The recent criticism surrounding Theranos, a privately held diagnostics company valued at about $9 billion, has been unfair, Theranos board member Richard Kovacevich said Monday.
He was responding to a series of Wall Street Journal reports raising questions about the accuracy of the proprietary method from Theranos — designed to conduct lab tests using only a small finger prick instead of drawing blood the traditional way with needles. The company stands by its claims, and CEO Elizabeth Holmes defended the work on CNBC in October.
